| Literature DB >> 35749639 |
Cristiane F Bortoncello1, Nicolas de Oliveira Cardoso2, Eduarda Z Salvador2, Richard C de Avila3, Wagner de L Machado2, Ygor A Ferrão1.
Abstract
OBJECTIVE: To evaluate the effectiveness of group cognitive-behavioral therapy (GCBT) for the treatment of adolescents with obsessive compulsive disorder (OCD).Entities:
Keywords: Group cognitive-behavioral therapy; adolescents; obsessive compulsive disorder
Year: 2022 PMID: 35749639 PMCID: PMC9375669 DOI: 10.47626/1516-4446-2021-2264
Source DB: PubMed Journal: Braz J Psychiatry ISSN: 1516-4446
Figure 1Flowchart. CY-BOCS = Children’s Yale-Brown Obsessive Compulsive Scale; OCD = obsessive-compulsive disorder; Y-BOCS = Yale-Brown Obsessive Compulsive Scale.
Characteristics of studies and interventions
| Reference and country | Study design | Protocol used | Intervention (comparison) | Duration of treatment | Weekly sessions (duration) | Family participation (how many/which sessions) | Outcome measures |
|---|---|---|---|---|---|---|---|
| Fischer, | NRCT | A standardized behavioral group treatment program for obsessive-compulsive disorder | GCBT (pre/post-test) | 7 weeks | 1 (1.5h) | 7 educational sessions (optional) open to everyone (family and clients) | CY-BOCS |
| Thienemann, | NRCT | OCD in Children and Adolescent: A Cognitive-Behavioral Treatment Manual | GCBT (pre/post-test) | 14 weeks | 1 (2h) | Last 15 min of each session + 1 session with the participation of parents and siblings | CY- BOCS |
| Himle, | NRCT | Group behavioral therapy for adolescents with obsessive-compulsive disorder | GCBT (pre/post-test) | 7 weeks | 1 (1.5h) | 1 optional weekly session with patients and family | CY-BOCS |
| Barrett, | RCT | Freedom From Obsessions and Compulsions Using Cognitive-Behavioral Strategies (FOCUS) | GCBFT (ICBFT and waitlist) | 14 weeks + 2 booster sessions after 1 month and after 3 months of the intervention | 1 (1.5h) | 50 min children10 min parents + children30 min parents (skills training) | CY-BOCS |
| Barrett, | 12 and 18 months follow-up | ||||||
| O’Leary, | 7-year follow-up | Y-BOCS | |||||
| Martin, | NRCT | How I ran OCD off My Land | GCBT (pre/post-test) | 14 weeks | 1 (1.5h) | Two simultaneous groups:60 min children (G1)60 min parents (G2)At the end of each session, the groups got together for 30 min | CY-BOCS |
| Asbahr, | RCT | How I ran OCD off My Land | GCBT (sertraline) | 12 weeks | 1 (1.5h) | Last 15 min of each session + 1 session with the participation of parents and siblings | CY-BOCS |
| Farrell, | NRCT | OCD Busters (Child and Adolescent Versions) | GCBT (pre/pos-test) | 13 weeks + 2 booster sessions after 1 month and after 3 months of the intervention | 1 (1.5h) | Last 15 min of each session + 3 group sessions with parents (1 h) and two individual sessions with each family (1 h) | CY-BOCS |
| Lavell, | 12 months follow-up | ||||||
| Fatori, | RCT | How I ran OCD off My Land | GCBT (FLX) | 14 weeks | 1 (1.7h) | Parents of the FLX group were invited to accompany their children during biweekly consultations with the doctor. Last 15 min of each session + 1 session with the participation of parents and siblings | Y-BOCS |
| Selles, | NRCT | OCD is Not the Boss of Me | GFCBT (pre/pos-test) | 12 weeks | 1 (1.5h) | Parents participated in a Parent Group and in the final 15-30 min of each session they join their children to answer questions and receive the homework | CY-BOCS |
| Shabani, | RCT | How I ran OCD off My Land[46] | GCBT + SSRI (ACT + SSRI and SSRI) | 12 weeks | 1 (1h) | Last 5 min of each session, they received a summary of what was discussed and were instructed not to reinforce obsessive behaviors | CY-BOCS |
ACT = acceptance and commitment therapy; CY-BOCS = Children’s Yale-Brown Obsessive Compulsive Scale; FLX = fluoxetine; GCBT = group cognitive-behavioral therapy; GCBFT = group cognitive-behavioral family therapy; GFCBT = group family-based cognitive behavioral therapy; ICBFT = individual cognitive-behavioral family therapy; NR = not reported; NRCT = non-randomized clinical trial; OCD = obsessive compulsive disorder; RCT = randomized clinical trial; SSRI = selective serotonin reuptake inhibitors; Y-BOCS = Yale-Brown Obsessive Compulsive Scale.
Characteristics of the participants
| Study | Sample size | Mean age (SD) | Sex ratio | Psychiatric comorbidities | SMP | Medication | Time of use |
|---|---|---|---|---|---|---|---|
| Fischer | 15 | 14.5 (NR) | 9M; 6F | NR | 67% | SSRI | 3 weeks BI |
| Thienemann | 18 | 15.2 (NR) | 12M; 6F | SOPH (n=3); MD (n=3); ED (n=1); SPPH (n=1); TD (n =1); TS (n=1); ID (n=1) | 83% | NR | NR |
| Himle | 19 | 14.63 (1.71) | 11M; 8F | MD (n=7); DYS (n=1); ADHD (n=4); ODD (n=2); SAD (n=4); PD (n=1); SOPH (n=1); AG (n=2); SPPH (n=2); GAD (n=1) | 68% | SSRI (n=17)Stimulant for ADHD (n=6) | 3 weeks BI |
| Barrett | 77 | ICBFT – 10.75 (2.54) | ICBFT (12M;12F) | GAD (n=46); SPPH (n=27); SOPH (n=15); SAD (n=13); DYS (n=4); MD (n=2) | ICBFT (12.5%) | NR | 3 months BI |
| GCBFT – 12.90 (2.30) | GCBFT (13M;16F) | GCBFT (20.7%) | |||||
| Waitlist – 11.75 (3.05) | Waitlist (13M;11F) | Waitlist (21%) | |||||
| Barrett | 48 | ICBFT – 12.91 (2.57) | ICBFT (11M;11F) | NR | ICBFT (9%) | NR | NR |
| GCBFT – 14.65 (2.30) | GCBFT (12M;14F) | GCBFT (15%) | |||||
| O’Leary | 38 | ICBFT – 17.6 (2.75) | ICBFT (9M;10F) | NR | 34% | SSRI | NR |
| GCBFT – 19.2 (2.81) | GCBFT (11M;8F) | ||||||
| Martin | 14 | 11.3 (NR) | 4M; 9F | ADHD (n=5); PDD or NVLD (n=4); TTM (n=2); SSPH (n=2); GAD (n=1); TD (n=1); SOPH (n=1) | 64% | SSRI(n=9); Stimulant for ADHD (n=4) | NR |
| Asbahr | 40 | GCBT – 13.7 (2.32) | GCBT (15M; 5F) | MD (n=7); mania (n=1); anxiety disorders (n=12); ODD (n=6); TD (n=21); enuresis (n=4); ADHD (n=9); ED (n=1) | Only group Sertraline | SSRI | - |
| Sertraline – 12.4 (2.76) | Sertraline (11M; 9F) | ||||||
| Farrell | 43 | 11.09(2.52) | 30M 13F | GAD (n=14); SAD (n=4); SOPH (n=8); SPPH (n=11); MD (n=3); DYS (n=2); ADHD (n=8); ODD (n=1); PDD (n=15) | 67% | SSRI | NR |
| Lavell | |||||||
| Fatori | 83 | GCBT – 11.4 (3.2) | GCBT (22M; 18F) | MD (n=16); anxiety disorders (n=65); disruptive disorders (n=23); TD (n=17) | Only group FLX | SSRI | - |
| FLX – 12.1 (3.1) | FLX (18M; 25F) | ||||||
| Selles | 85 | 13.9 (2.49) | 39M;46F | GAD (n=21); TD; (n=13); ADHD (n=12); AS (n=12); SPPH (n=4); SAD (n=4); ODD (n=2); MD (n=1) | 44.7% | NR | NR |
| Shabani | 69 | GCBT – 14.95 (1.78) | GCBT (12M;10F) | NR | 100% | SSRI | 3 months BI |
| ACT – 14.95 (1.43) | ACT (12M;10F) | ||||||
| SSRI – 14.96 (1.24) | SSRI (14M;11F) |
ACT = acceptance and commitment therapy; AG = agoraphobia; ADHD = attention deficit/hyperactivity disorder; BI = before intervention; DYS = dysthymic disorder; ED = eating disorder; F = female; FLX = fluoxetine; GAD = generalized anxiety disorder; GCBT = group cognitive-behavioral therapy; GCBFT = group cognitive-behavioral family therapy; ICBFT = individual cognitive-behavioral family therapy; ID = intellectual disability; M = male; MD = major depression; NR = not reported; NVLD = non-verbal learning disorder; ODD = oppositional defiant disorder; PD = panic disorder; PDD = pervasive developmental disorder; SA = social anxiety; SAD = separation anxiety disorder; SD = standard deviation; SMP = sample medication use; SOPH = social phobia; SPPH = specific phobia; SSRI = selective serotonin reuptake inhibitors; TD = tic disorder; TS = Tourette syndrome; TTM = trichotillomania.
Figure 2Fixed effects, standard mean difference (SMD), and accompanying 95% confidence interval (CI) for group cognitive-behavioral therapy (GCBT) interventions on OCD scores. GCBFT = group cognitive-behavioral family therapy; ICBFT = individual cognitive-behavioral family therapy; NRCT = non-randomized controlled trial; RCT = randomized controlled trial; SD = standard deviation; SSRI = selective serotonin reuptake inhibitors.
Risk of bias in included studies
| Study: ROBINS-I | Confounding bias | Selection bias | Classification bias | Deviation bias | Missing data bias | Measurement bias | Reporting bias |
|---|---|---|---|---|---|---|---|
| Fischer | + | + | - | - | - | - | ? |
| Thienemann | + | - | - | - | - | ? | ? |
| Himle | + | - | - | - | - | - | ? |
| Martin | + | - | - | - | - | - | ? |
| Farrell, | + | - | - | - | - | ? | ? |
| Selles | + | - | - | - | - | ? | ? |
Percentage of the sample with previous experience with CBT.
+ = high risk of bias; - = low risk of bias; ? = unclear risk of bias; RoB = Cochrane Collaboration risk of bias tool; ROBINS-I = Cochrane risk of bias tool to assess non-randomized studies of interventions.